New stock news | Weijian Medical filed a listing application with the Hong Kong Stock Exchange for the second time.

According to the financial news app Securities Times, it was disclosed by the Hong Kong Stock Exchange on June 25th that Weijian International Holdings Group Limited (referred to as Weijian Medicine) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. This is the second time the company has submitted the application, having previously submitted a listing application on November 7, 2025. The prospectus shows that Weijian Medicine is a comprehensive pharmaceutical company in China that focuses on the treatment of kidney diseases, with increasingly strong capabilities in drug development, production, and commercialization. The company is committed to providing diversified treatment solutions for kidney and blood diseases, as well as other major diseases. The company has built a diverse and differentiated product portfolio that covers a wide range of kidney disease areas, and extends to other major disease areas such as blood, respiratory, and skin diseases.